Discover a study that has revealed a new potential mechanism of understanding inflammation in ulcerative colitis.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of ...

Johnson & Johnson (J&J) has shared positive long-term results from a phase 3 trial of its dual-acting IL-23 inhibitor Tremfya ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...

Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrierData presented at Digestive Disease Week in San ...

New Panthers wide receiver Hunter Renfrow on Thursday discussed his battle with ulcerative colitis, a chronic inflammatory ...

Anjali (name changed), a healthy woman in her late 30s, presented with sudden onset of chronic abdominal pain. She was also experiencing diarrhea with blood and mucus ...

To evaluate the therapeutic value of mirikizumab in IBD, researchers conducted a systematic review and meta-analysis of ...

Crohn’s Disease and Ulcerative Colitis affects more than a million people including their families in Southern California ...

The two major types of IBD―Crohn’s disease and ulcerative colitis―present with overlapping but distinct symptoms. Crohn’s ...

Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis ...